Gen Digital Inc (GEN)
22.29
+1.46%
Gen Digital Inc (GEN) is currently trading at $22.29. This represents a gain of 1.46% from the previous session. With a market capitalization of $13.48B, GEN is a key component of the Technology sector. Investors looking to trade GEN should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade GEN commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Gen Digital Inc (GEN) shows a bullish trend. Analysts are watching the 22.39 level closely.
Fundamentals
Mkt Cap13.48B
P/E Ratio0.0000
Volume5,605,035
60-Day Technical Chart
Advanced Charting
Need more indicators for GEN? Use the world's #1 platform.
Open GEN on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $22
| Metric |
GEN +1.46% |
BMNR +10.60% |
HL -1.40% |
NCLH -0.63% |
|---|---|---|---|---|
| Price | $22.29 | $21.51 | $23.31 | $23.81 |
| Mkt Cap | $13.48B | $9.80B | $15.63B | $10.82B |
| - | View → | View → | View → |
Latest Headlines
Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin
Investor's Business Daily • Feb 23, 2026
Gen Digital Inc. $GEN Shares Bought by Rice Partnership LLC
MarketBeat • Feb 24, 2026
Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide (NVO:NYSE)
Seeking Alpha • Feb 23, 2026
Novo Nordisk’s stock closes at 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial
MarketWatch • Feb 23, 2026
Novo Nordisk Shares Dive ~11% as Next-Gen Weight Loss Drug CagriSema Falls Short of Eli Lilly's Flagship Product
AASTOCKS.com • Feb 23, 2026
● Gemini Agentic AI Analyst Insight for GEN
Market Education
- Trump’s Latest Tariffs Send Shockwaves Across U.S. Economy Sep 26, 2025
- From Small Players to Market Movers: How Former Small Caps Are Scaling Up Sep 27, 2025
- Investing $100: Options and Tools for Small Investments - many drops make an Ocean Jul 15, 2023
External Research